Method for evaluating samples, method for analysis, method for detecting deteriorated samples, marker for detecting deteriorated plasma samples, and marker for detecting deteriorated serum samples

By employing specific markers and mass spectrometry techniques, the method accurately evaluates plasma and serum sample quality, addressing variations due to preparation and storage conditions, and improving the reliability of analytical results.

JP7578125B2Active Publication Date: 2024-11-06SHIMADZU SEISAKUSHO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2022144323
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-05-09
Filing Date
2022-09-12
Publication Date
2024-11-06
Estimated Expiration
2040-01-27

AI Technical Summary

Technical Problem

Existing methods for evaluating plasma and serum samples are hindered by variations in results due to differences in sample preparation and storage conditions, leading to inaccurate quality assessment.

Method used

The use of specific markers such as 1,6-anhydroglucose, 1-hexadecanol, and others to evaluate the quality of plasma and serum samples based on their intensity, employing mass spectrometry techniques like GC/MS and LC/MS to detect these markers, allowing for accurate quality evaluation and detection of degraded samples.

Benefits of technology

Enables precise assessment of sample quality by identifying markers affected by preparation and storage conditions, enhancing the reliability of analytical results by excluding degraded samples and ensuring consistent sample quality for analysis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007578125000016
    Figure 0007578125000016
  • Figure 0007578125000017
    Figure 0007578125000017
  • Figure 0007578125000018
    Figure 0007578125000018
Patent Text Reader

Abstract

Appropriate markers allow accurate assessment of the quality of plasma or serum samples. [Solution] A method for evaluating a sample comprises obtaining a plasma sample prepared from human blood, detecting a predetermined molecule in the plasma sample, and evaluating the quality of the plasma sample based on the intensity of the molecule obtained by the detection.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for evaluating a sample, an analytical method, a method for detecting a degraded sample, a marker for detecting a degraded plasma sample, and a marker for detecting a degraded serum sample. [Background technology]

[0002] Methods are being studied for detecting molecules contained in plasma or serum by analysis such as mass spectrometry to obtain information for evaluating the risk of developing a disease, diagnosing the disease, predicting prognosis, etc. In such analyses, the results obtained may vary depending on the conditions under which the plasma or serum samples are prepared or stored.

[0003] In Non-Patent Document 1, the change in the amount of detected metabolites depending on the preparation or storage conditions of plasma or serum samples is observed by capillary electrophoresis-mass spectrometry. In Non-Patent Document 2, a similar observation is performed by gas chromatography / mass spectrometry and liquid chromatography / mass spectrometry. In Non-Patent Document 3 and Non-Patent Document 4, it is proposed to search for molecules whose detection amount changes depending on the preparation or storage conditions as quality evaluation markers. [Prior art documents] [Non-patent literature]

[0004] [Non-Patent Document 1] Hirayama A, Sugimoto M, Suzuki A, Hatakeyama Y, Enomoto A, Harada S, Soga T, Tomita M, Takebayashi T. "Effects of processing and storage conditions on charged metabolomic profiles in blood." Electrophoresis, (Germany), Wiley-VCH, September 2015, Volume 36, Issue 18, p.2148-2155 [Non-Patent Document 2] Nishiumi S, Suzuki M, Kobayashi T, Yoshida M. "Differences in metabolite profiles caused by pre-analytical blood processing procedures." Journal of bioscience and bioengineering, (Japan), Society for Bioscience and Bioengineering, Japan, May 2018, Volume 125, Issue 5, p.613-618 [Non-Patent Document 3] Kamlage B, Maldonado SG, Bethan B, Peter E, Schmitz O, Liebenberg V, Schatz P. "Serum metabolomics reveals γ-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease." Clinical Chemistry, (USA), American Association For Clinical Chemistry, February 2014, Volume 60, Issue 2, p.399-412 [Non-Patent Document 4] Kasuga, et al. (ed.), Minegishi, et al. (ed.), "Report on the handling of biological samples for omics research, [online], August 1, 2017, Japan Agency for Medical Research and Development, [searched March 22, 2019], Internet (https: / / www.biobank.amed.go.jp / 2017 / 08 / 08 / content / pdf / medical / omicsreport0810.pdf) Summary of the Invention [Problem to be solved by the invention]

[0005] It is desirable to have suitable markers to accurately assess the quality of plasma or serum samples. [Means for solving the problem]

[0006] A first aspect of the present invention comprises obtaining a plasma sample prepared from human blood and detecting in said plasma sample the following: 1,6-anhydroglucose, 1-hexadecanol, 2-aminobutyric acid, 2-ketobutyric acid, 2'-deoxyuridine, 2-hydroxyisocaproic acid, 2-hydroxypyridine, 3-aminoisobutyric acid, 3-sulfinoalanine, 3-phenyllactic acid, 4-aminobutyric acid, 4-hydroxyphenyllactic acid, 4-hydroxyproline, 5-glutamylcysteine, N6-acetyllysine, N-acetylserine, S-adenosylhomocysteine, S-adenosylmethionine, aconitic acid, ascorbic acid, asparagine, aspartic acid, acetylcarnitine, azelaic acid, adenine, adenosine, adenosine monophosphate, adenosine 3',5'-cyclic monophosphate, arachidonic acid, alanine, allantoin, argininosuccinic acid, arginine, isoleucine, inosine, indoxyl sulfate, uridine, octadecanol, ornithine, oleic acid, caproic acid, galacturonic acid, carnitine, xanthine, xylose, kynurenine, quinolinic acid, guanosine, guanosine monophosphate, glyoxylic acid, glycolic acid, glycine, glycerol-3-phosphate, glutamine, glutamic acid, creatinine, creatine, cholic acid, succinic acid, choline, cholesterol, cystathionine, cystine, cysteine, citicoline, cytidine, cytidine monophosphate, cytosine, citrulline, dihydrouracil, dihydroxyacetone phosphate, dimethylglycine, oxalic acid, scyllo-inositol, sucrose, stearic acid, serotonin, sorbose, The present invention relates to a method for evaluating a sample, comprising: detecting at least one molecule selected from the group consisting of symmetric dimethylarginine, dopa, dopamine, docosahexaenoic acid, tryptamine, tryptophan, trehalose, nicotinamide, uric acid, paraxanthine, palmitic acid, pantothenic acid, histamine, histidine, asymmetric dimethylarginine, hydroquinone, hypoxanthine, hypotaurine, psicose, proline, boric acid, homocysteine, maleic acid, mannose, myristic acid, methionine sulfoxide, methionine sulfone, monostearin, lactitol, lactose, linoleic acid, ribulose, ribose, ribonic acid, malic acid, leucine, and uric acid; and evaluating the quality of the plasma sample based on the intensity of the molecule obtained by the detection. A second aspect of the present invention relates to an analytical method comprising evaluating a plasma sample by the sample evaluation method of the first aspect, and analyzing the plasma sample based on said evaluation. A third aspect of the present invention comprises obtaining a plasma sample prepared from human blood and detecting in said plasma sample the following: 1,6-anhydroglucose, 1-hexadecanol, 2-aminobutyric acid, 2-ketobutyric acid, 2'-deoxyuridine, 2-hydroxyisocaproic acid, 2-hydroxypyridine, 3-aminoisobutyric acid, 3-sulfinoalanine, 3-phenyllactic acid, 4-aminobutyric acid, 4-hydroxyphenyllactic acid, 4-hydroxyproline, 5-glutamylcysteine, N6-acetyllysine, N-acetylserine, S-adenosylhomocysteine, S-adenosylmethionine ... Thionine, aconitic acid, ascorbic acid, asparagine, aspartic acid, acetylcarnitine, azelaic acid, adenine, adenosine, adenosine monophosphate, adenosine 3',5'-cyclic monophosphate, arachidonic acid, alanine, allantoin, argininosuccinic acid, arginine, isoleucine, inosine, indoxyl sulfate, uridine, octadecanol, ornithine, oleic acid, caproic acid, galacturonic acid, carnitine, xanthine, xylose, kynurenine, quinolinic acid, guanosine, guanosine monophosphate, glyoxylic acid, glycolic acid, Syn, glycerol-3-phosphate, glutamine, glutamic acid, creatinine, creatine, cholic acid, succinic acid, choline, cholesterol, cystathionine, cystine, cysteine, citicoline, cytidine, cytidine monophosphate, cytosine, citrulline, dihydrouracil, dihydroxyacetone phosphate, dimethylglycine, oxalic acid, scyllo-inositol, sucrose, stearic acid, serotonin, sorbose, symmetric dimethylarginine, dopa, dopamine, docosahexaenoic acid, tryptamine, tryptophan, trehalose, nicotinamide, urine and detecting at least one molecule selected from the group consisting of dimethylarginine, paraxanthine, palmitic acid, pantothenic acid, histamine, histidine, asymmetric dimethylarginine, hydroquinone, hypoxanthine, hypoxanthine, hypotaurine, psicose, proline, boric acid, homocysteine, maleic acid, mannose, myristic acid, methionine sulfoxide, methionine sulfone, monostearin, lactitol, lactose, linoleic acid, ribulose, ribose, ribonic acid, malic acid, leucine, and uric acid. A fourth aspect of the present invention is a method for producing a lactic acid molecule comprising the steps of: 1,6-anhydroglucose, 1-hexadecanol, 2-aminobutyric acid, 2-ketobutyric acid, 2'-deoxyuridine, 2-hydroxyisocaproic acid, 2-hydroxypyridine, 3-aminoisobutyric acid, 3-sulfinoalanine, 3-phenyllactic acid, 4-aminobutyric acid, 4-hydroxyphenyllactic acid, 4-hydroxyproline, 5-glutamylcysteine, N6-acetyllysine, N-acetylserine, S-adenosylhomocysteine, S-adenosylmethionine, aconitic acid, ascorbic acid, asparagine , aspartic acid, acetylcarnitine, azelaic acid, adenine, adenosine, adenosine monophosphate, adenosine 3',5'-cyclic monophosphate, arachidonic acid, alanine, allantoin, argininosuccinic acid, arginine, isoleucine, inosine, indoxyl sulfate, uridine, octadecanol, ornithine, oleic acid, caproic acid, galacturonic acid, carnitine, xanthine, xylose, kynurenine, quinolinic acid, guanosine, guanosine monophosphate, glyoxylic acid, glycolic acid, glycine, glycerol-3-phosphate , glutamine, glutamic acid, creatinine, creatine, cholic acid, succinic acid, choline, cholesterol, cystathionine, cystine, cysteine, citicoline, cytidine, cytidine monophosphate, cytosine, citrulline, dihydrouracil, dihydroxyacetone phosphate, dimethylglycine, oxalic acid, scyllo-inositol, sucrose, stearic acid, serotonin, sorbose, symmetric dimethylarginine, dopa, dopamine, docosahexaenoic acid, tryptamine, tryptophan, trehalose, nicotinamide, uric acid, parachi The present invention relates to a marker for detecting deteriorated plasma samples, which comprises at least one molecule selected from the group consisting of santhin, palmitic acid, pantothenic acid, histamine, histidine, asymmetric dimethylarginine, hydroquinone, hypoxanthine, hypoxanthine, hypotaurine, psicose, proline, boric acid, homocysteine, maleic acid, mannose, myristic acid, methionine sulfoxide, methionine sulfone, monostearin, lactitol, lactose, linoleic acid, ribulose, ribose, ribonic acid, malic acid, leucine and uric acid. A fifth aspect of the present invention comprises obtaining a serum sample prepared from human blood, and detecting in said serum sample 1,6-anhydroglucose, 1-hexadecanol, 2-aminooctanoic acid, 2-aminobutyric acid, 2-ketoisovaleric acid, 2-hydroxyglutaric acid, 2-hydroxypyridine, 3-aminoisobutyric acid, 3-aminopropionic acid, β-alanine, 3-indolepropionic acid, 3-sulfinoalanine, 3-hydroxyanthranilic acid, 3-hydroxyisovaleric acid, 3-hydroxypyruvic acid, 3-hydroxypropionic acid, 3-phenyllactic acid, 4-hydroxyphenyllactic acid, 4-hydroxyproline, 5-hydroxymethyl-2-furancarboxylic acid, N6-acetyl lysine, N-acetylglutamine ... Acetylserine, S-adenosylhomocysteine, aconitic acid, adipic acid, ascorbic acid, asparagine, aspartic acid, acetylcarnitine, acetylglycine, acetoacetic acid, azelaic acid, adenine, adenosine, adenosine monophosphate, adenosine 3',5'-cyclic monophosphate, arachidonic acid, alanine, allantoin, argininosuccinic acid, arginine, allose, benzoic acid, isoleucine, inositol, inosine, uracil, uridine, eicosapentaenoic acid, erythrulose, octadecanol, ornithine, oleamide, cadaverine, caproic acid, galacturonic acid, carnitine, carnosine, xanthine, xylitol, xylulose, xylose, kynurenine, guanosine, guanosine 3',5′-Cyclic acid 1-phosphate, glyoxylic acid, glycolic acid, glycine, glycerol-3-phosphate, glucosamine, gluconic acid, glutamic acid, glutaric acid, creatinine, creatine, cholic acid, succinic acid, choline, sarcosine, cystine, cysteine, cytidine, citramalic acid, citrulline, dihydrouracil, dihydroxyacetone phosphate, dimethylglycine, oxalic acid, scyllo-inositol, sucrose, stearic acid, serine, serotonin, sorbitol, sorbose, tyramine, tyrosine, decanoic acid, dopa, dopamine, docosahexaenoic acid, tryptophan, threonine, threonic acid, trehalose, nicotinamide, paraxanthine, valine, pantothenic acid, histidine, asymmetric dimethylarginine, hydroxylamine and evaluating the quality of the serum sample based on the intensity of the molecule obtained by the detection. A sixth aspect of the present invention relates to an analytical method comprising evaluating a serum sample by the sample evaluation method of the fifth aspect, and analyzing the serum sample based on the evaluation. A seventh aspect of the present invention comprises obtaining a serum sample prepared from human blood, and detecting in said serum sample 1,6-anhydroglucose, 1-hexadecanol, 2-aminooctanoic acid, 2-aminobutyric acid, 2-ketoisovaleric acid, 2-hydroxyglutaric acid, 2-hydroxypyridine, 3-aminoisobutyric acid, 3-aminopropionic acid, β-alanine, 3-indolepropionic acid, 3-sulfinoalanine, 3-hydroxyanthranilic acid, 3-hydroxyisovaleric acid, 3-hydroxypyruvic acid, 3-hydroxypropionic acid, 3-phenyllactic acid, 4-hydroxyphenyllactic acid, 4-hydroxyproline, 5-hydroxymethyl-2-furancarboxylic acid, N6-acetyl lysine, N-acetylglutamine ... Acetylserine, S-adenosylhomocysteine, aconitic acid, adipic acid, ascorbic acid, asparagine, aspartic acid, acetylcarnitine, acetylglycine, acetoacetic acid, azelaic acid, adenine, adenosine, adenosine monophosphate, adenosine 3',5'-cyclic monophosphate, arachidonic acid, alanine, allantoin, argininosuccinic acid, arginine, allose, benzoic acid, isoleucine, inositol, inosine, uracil, uridine, eicosapentaenoic acid, erythrulose, octadecanol, ornithine, oleamide, cadaverine, caproic acid, galacturonic acid, carnitine, carnosine, xanthine, xylitol, xylulose, xylose, kynurenine, guanosine, guanosine 3',5′-cyclic 1-phosphate, glyoxylic acid, glycolic acid, glycine, glycerol-3-phosphate, glucosamine, gluconic acid, glutamic acid, glutaric acid, creatinine, creatine, cholic acid, succinic acid, choline, sarcosine, cystine, cysteine, cytidine, citramalic acid, citrulline, dihydrouracil, dihydroxyacetone phosphate, dimethylglycine, oxalic acid, scyllo-inositol, sucrose, stearic acid, serine, serotonin, sorbitol, sorbose, tyramine, tyrosine, decanoic acid, dopa, dopamine, docosahexaenoic acid, tryptophan, threonine, threonic acid, trehalose, nicotinamide, paraxanthine, valine, pantothenic acid, histidine, unpaired and detecting at least one molecule selected from the group consisting of symmetric dimethylarginine, hydroxylamine, hypoxanthine, hypotaurine, pyridoxamine, pyruvic acid-oxime, pyruvic acid, phenylalanine, phenylpyruvic acid, phenylbutyric acid, psicose, putrescine, proline, pelargonic acid, boric acid, homocysteine, margaric acid, maleic acid, myo-inositol, myristic acid, mesoerythritol, methionine, methionine sulfoxide, monostearin, lactitol, lactose, ribitol, ribulose, ribose, ribonic acid, ribonic acid lactone, malic acid, leucine, benzoic acid, symmetric dimethylarginine, and uric acid. The eighth aspect of the present invention relates to an ester of 1,6-anhydroglucose, 1-hexadecanol, 2-aminooctanoic acid, 2-aminobutyric acid, 2-ketoisovaleric acid, 2-hydroxyglutaric acid, 2-hydroxypyridine, 3-aminoisobutyric acid, 3-aminopropionic acid, β-alanine, 3-indolepropionic acid, 3-sulfinoalanine, 3-hydroxyanthranilic acid, 3-hydroxyisovaleric acid, 3-hydroxypyruvic acid, 3-hydroxypropionic acid, 3-phenyllactic acid, 4-hydroxyphenyllactic acid, 4-hydroxyproline, 5-hydroxymethyl-2-furancarboxylic acid, N6-acetyllysine, N-acetylglutamine, N-acetylserine, S-adenosylhomosyl Stain, aconitic acid, adipic acid, ascorbic acid, asparagine, aspartic acid, acetylcarnitine, acetylglycine, acetoacetic acid, azelaic acid, adenine, adenosine, adenosine monophosphate, adenosine 3',5'-cyclic monophosphate, arachidonic acid, alanine, allantoin, argininosuccinic acid, arginine, allose, benzoic acid, isoleucine, inositol, inosine, uracil, uridine, eicosapentaenoic acid, erythrulose, octadecanol, ornithine, oleamide, cadaverine, caproic acid, galacturonic acid, carnitine, carnosine, xanthine, xylitol, xylulose, xylose, kynurenine, guanosine, guanosine 3',5'-Cyclic 1-phosphate, glyoxylic acid, glycolic acid, glycine, glycerol-3-phosphate, glucosamine, gluconic acid, glutamic acid, glutaric acid, creatinine, creatine, cholic acid, succinic acid, choline, sarcosine, cystine, cysteine, cytidine, citramalic acid, citrulline, dihydrouracil, dihydroxyacetone phosphate, dimethylglycine, oxalic acid, scyllo-inositol, sucrose, stearic acid, serine, serotonin, sorbitol, sorbose, tyramine, tyrosine, decanoic acid, dopa, dopamine, docosahexaenoic acid, tryptophan, threonine, threonic acid, trehalose, nicotinamide, paraxanthine, valine, pantothenic acid, histidine The present invention relates to a marker for detecting deteriorated serum samples, comprising at least one molecule selected from the group consisting of asymmetric dimethylarginine, hydroxylamine, hypoxanthine, hypotaurine, pyridoxamine, pyruvic acid oxime, pyruvic acid, phenylalanine, phenylpyruvic acid, phenylbutyric acid, psicose, putrescine, proline, pelargonic acid, boric acid, homocysteine, margaric acid, maleic acid, myo-inositol, myristic acid, mesoerythritol, methionine, methionine sulfoxide, monostearin, lactitol, lactose, ribitol, ribulose, ribose, ribonic acid, ribonic acid lactone, malic acid, leucine, benzoic acid, symmetric dimethylarginine, and uric acid. Effect of the Invention

[0007] According to the present invention, the quality of a plasma or serum sample can be accurately evaluated based on an appropriate marker. [Brief description of the drawings]

[0008] [Figure 1] FIG. 1 is a flowchart showing the flow of an analysis method according to one embodiment. [Diagram 2] FIG. 2 is a conceptual diagram illustrating the preparation of a plasma sample. [Diagram 3] FIG. 3 is a conceptual diagram illustrating the preparation of a serum sample. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] Hereinafter, an embodiment of the present invention will be described with reference to the drawings. The sample evaluation method of the following embodiment detects a predetermined molecule in a sample derived from human blood, and evaluates the quality of the sample based on the detection.

[0010] The above-mentioned predetermined molecule is a molecule whose concentration differs between a sample that is considered to be of low quality or deteriorated and a sample that is considered to be of non-low quality or deteriorated. Here, "low quality" and "deteriorated" mean that a quantitative value, such as a concentration, corresponding to at least a part of the molecules to be analyzed contained in the sample may have changed, and it is difficult or impossible to obtain the quantitative value before the change. Since information about the quality of the sample can be obtained by detecting the above-mentioned predetermined molecule in the sample, the above-mentioned predetermined molecule functions as a marker when evaluating the quality of the sample or for detecting a deteriorated sample, and is hereinafter referred to as a marker.

[0011] 1 is a flow chart showing the flow of an analysis method including a sample evaluation method of this embodiment. In step S101, a plasma or serum sample is obtained. Specific molecules detected as markers will be described later.

[0012] (About the sample) The sample is not particularly limited as long as it is a plasma sample or serum sample prepared from human blood (hereinafter referred to as a blood donor). The blood donor may be a healthy individual or a patient with some disease. The sample evaluation method of the present embodiment can be applied to samples that are subjected to analysis for any purpose, such as research purposes, in addition to analysis for testing or diagnosis of blood donors.

[0013] A suitable example is a cohort study in which plasma or serum samples are prepared and stored in multiple facilities, and these samples are subjected to analysis at a certain time. In such a case, if the preparation or storage conditions are different in different facilities, the analysis results will vary, making it difficult to obtain reliable results. Therefore, by performing the sample evaluation method of the present embodiment on at least a portion of the stored samples before analysis, samples that are assumed to have deteriorated can be detected and excluded from the analysis, thereby improving the reliability of the analysis. As described above, the sample evaluation method of this embodiment is not limited to the above-mentioned research, but may also be used in medical institutions or testing institutions to evaluate the quality of plasma or serum samples obtained from patients.

[0014] After step S101 is completed, step S103 is started. In step S103, the plasma or serum sample obtained in step S101 is analyzed to detect the marker in vitro. This analysis is called a first analysis.

[0015] (Regarding marker detection) The method for detecting a marker in a plasma or serum sample is not particularly limited as long as it is possible to determine with the desired accuracy whether the concentration of the detected marker satisfies a predetermined condition, such as a threshold value or a numerical range. In the following embodiments, "detecting a marker" refers to detecting a marker contained in a plasma sample or serum sample in order to quantify the marker, and also includes cases in which a substance derived from a marker, such as an ionized marker, a dissociated marker or its ions, or a derivative of a marker or its ions, is directly detected but the marker itself is not directly detected.

[0016] From the viewpoint of suitably separating and detecting a target marker from a sample containing various kinds of substances, the marker contained in the sample is preferably detected by mass spectrometry, and more preferably by gas chromatography / mass spectrometry (hereinafter referred to as GC / MS) or liquid chromatography / mass spectrometry (hereinafter referred to as LC / MS). Here, GC / MS and LC / MS are also known as tandem mass spectrometry and MS. n This also includes cases where multiple mass separations such as those described above are performed.

[0017] Therefore, a mass spectrometer is preferable as a detection device for detecting markers contained in a sample in the first analysis. In particular, it is preferable to perform GC / MS using a gas chromatograph-mass spectrometer (hereinafter referred to as GC-MS) or LC / MS using a liquid chromatograph-mass spectrometer (hereinafter referred to as LC-MS). The mass spectrometer may be a single mass spectrometer or a mass spectrometer capable of two or more stages of mass separation. The type of mass analyzer that performs these mass separations inside the mass spectrometer is not particularly limited, and may include one or more of a quadrupole mass filter, an ion trap, a time-of-flight mass analyzer, and the like, in appropriate combination.

[0018] The data obtained by the detection of the marker in the first analysis (hereinafter referred to as the first data) is appropriately stored in any storage medium. The first data is not particularly limited as long as it indicates a detection signal generated by the detection of the marker. When the first analysis is mass spectrometry, the first data can be data corresponding to a mass chromatogram (hereinafter referred to as mass chromatogram data) or data corresponding to a mass spectrum (hereinafter referred to as mass spectrum data), etc. The mass chromatogram data is data indicating the magnitude of the detection signal at each retention time. The mass spectrum data is data indicating the magnitude of the detection signal corresponding to each m / z (corresponding to the mass-to-charge ratio).

[0019] After step S103 is completed, step S105 is started. In step S105, the quality of the plasma or serum sample is evaluated based on the data obtained by the detection of the markers in step S103.

[0020] In step S105, the marker is quantified by data analysis of the first data. The calculation in step S105 may be performed manually, but is preferably performed by a control device including a CPU or the like. The concentration of the marker is calculated using the first data and calibration data such as a calibration curve or a relative response coefficient obtained in advance. For example, when GC / MS or LC / MS is performed in step S103, the peak area or peak intensity of a peak corresponding to the marker in the mass chromatogram is calculated as the magnitude of the detection signal corresponding to the marker (hereinafter referred to as detection intensity). The detection intensity is converted using the calibration data to obtain the concentration of the marker in the plasma sample or serum sample.

[0021] Once the concentration of the marker is obtained, it is determined whether or not the concentration satisfies a predetermined condition (hereinafter referred to as quality condition) based on a threshold value or a numerical range corresponding to the marker. Tables A to M described later list compounds that serve as markers indicating whether or not a predetermined quality condition for preparation or storage of plasma and serum samples is satisfied. For example, a threshold value is pre-defined for the markers shown in Tables A to M that increase under predetermined preparation or storage conditions, and the obtained concentration of the marker is higher than the threshold value. In this case, the sample does not satisfy the quality condition, and the sample can be evaluated as being of insufficient or low quality, etc. Suppose that a threshold value is pre-defined for the markers shown in Tables A to M that decrease under predetermined preparation or storage conditions, and the obtained concentration of the marker is lower than the threshold value. In this case, the sample does not satisfy the quality condition, and the sample can be evaluated as being of insufficient or low quality, etc. Suppose that a numerical range is pre-defined for the markers shown in Tables A to M that may increase or decrease under predetermined preparation or storage conditions, but may vary, and the concentration of the marker is outside the numerical range. In this case, the sample does not meet the quality conditions and the sample can be evaluated as being of insufficient or low quality, etc.

[0022] When multiple markers are used to evaluate the quality of a sample, if any one or all of the multiple markers, or any number of markers, do not satisfy the quality conditions, the quality of the sample can be evaluated as low, etc. In Tables A to M, there are markers whose detection intensity is increased under certain conditions compared to the conditions to be compared, markers whose detection intensity is decreased, and markers whose detection intensity may increase or decrease but fluctuate, and one or more of these markers can be appropriately combined to evaluate the quality or detect a degraded plasma sample or degraded serum sample. There are no particular limitations on the method of setting the quality conditions, the evaluation algorithm, etc.

[0023] For some markers, it is also possible to assess the quality of the sample as being affected due to differences in specific conditions in the preparation of the plasma or serum sample.

[0024] FIG. 2 is a conceptual diagram for explaining the preparation of a plasma sample. In the preparation of a plasma sample, blood is collected from a blood donor and stored in a blood collection tube containing an anticoagulant such as EDTA. After collection, the blood is mixed by shaking the blood collection tube (arrow A1). After mixing, the blood is cooled and left to stand at a low temperature such as 4°C (arrow A2). After standing, the blood is centrifuged (arrow A3). The conditions of the centrifugation are not particularly limited as long as the plasma is separated, and for example, the centrifugation is performed at 4°C for 15 minutes at 3000 rpm. After centrifugation, the blood is separated into blood cells, which are a precipitate, and the supernatant, and the plasma contained in the supernatant is separated (arrow A4). The separated plasma is frozen and stored as a plasma sample (arrow A5).

[0025] If the marker affected by the time from blood collection to centrifugation does not meet the quality conditions, the plasma sample can be evaluated as having a condition in which the time from blood collection to centrifugation does not meet the conditions in the preparation of the plasma sample. Alternatively, the time from blood collection to centrifugation can be estimated by detecting the marker. If the marker affected by the time from blood collection to cooling the blood does not meet the quality conditions, the plasma sample can be evaluated as having a condition in which the time from blood collection to standing at 4°C does not meet the conditions in the preparation of the plasma sample. Alternatively, the time from blood collection to cooling the blood can be estimated by detecting the marker. If the marker affected by the number of freeze-thaw cycles does not meet the quality conditions, the plasma sample can be evaluated as having a condition in which the number of freeze-thaw cycles does not meet the conditions in the preparation or storage of the plasma sample. Alternatively, the number of freeze-thaw cycles can be estimated by detecting the marker. Information obtained by such quality evaluation can be used to adjust the plasma sample used for analysis to certain preparation or storage conditions, etc.

[0026] FIG. 3 is a conceptual diagram for explaining the preparation of a serum sample. In preparing a serum sample, blood is collected from a blood donor and stored in a blood collection tube or the like that does not contain an anticoagulant. After blood collection, the blood is mixed by shaking the blood collection tube (arrow A10). After mixing, the blood is left to stand at room temperature (arrow A20). After standing, the blood is centrifuged (arrow A30). The conditions of the centrifugation are not particularly limited as long as the serum is separated, and for example, the centrifugation is performed at room temperature for 5 minutes at 3500 rpm. After centrifugation, the blood is separated into a blood clot as a precipitate, a serum separating agent, and serum, and the serum contained in the supernatant is separated (arrow A40). The separated serum is frozen and stored as a serum sample (arrow A50).

[0027] When the marker affected by the time from blood collection to centrifugation does not meet the quality conditions, the serum sample can be evaluated as if the time from blood collection to centrifugation did not meet the conditions in the preparation of the serum sample. Alternatively, the time from blood collection to centrifugation can be estimated by detecting the marker. When the marker affected by the time from centrifugation to fractionation does not meet the quality conditions, the serum sample can be evaluated as if the time from centrifugation to fractionation did not meet the conditions in the preparation of the serum sample. Alternatively, the time from centrifugation to fractionation can be estimated by detecting the marker. When the marker affected by the number of freeze-thaw cycles does not meet the quality conditions, the serum sample can be evaluated as if the number of freeze-thaw cycles did not meet the conditions in the preparation of the serum sample. Alternatively, the number of freeze-thaw cycles can be estimated by detecting the marker. Information obtained by such quality evaluation can be used to adjust the serum sample used for analysis to certain preparation or storage conditions, etc.

[0028] Returning to FIG. 1, when step S105 is completed, step S107 is started. Based on the evaluation obtained in step S105, the plasma sample or serum sample is analyzed. This analysis is called the second analysis. Based on the evaluation, low-quality plasma or serum samples, or samples obtained from facilities that have prepared or stored these low-quality samples, can be excluded from the analysis. Alternatively, based on the evaluation, information indicating the reliability of the second analysis may be generated and added to the data obtained by the analysis. In the second analysis, as described above, analysis is performed for any purpose, such as research purposes, in addition to analysis for testing or diagnosis of blood donors. From the viewpoint of increasing accuracy, it is preferable that the first analysis and the second analysis are performed by the same type of analysis method, but this is not particularly limited, and the second analysis can be performed by any analysis method. Information obtained by the second analysis is output to a display device such as a liquid crystal monitor as appropriate. When step S107 is completed, the process is terminated.

[0029] (Regarding markers in plasma samples) (1A) For plasma samples, the markers were 1,6-anhydroglucose, 1-hexadecanol, 2-aminobutyric acid, 2-ketobutyric acid, 2'-deoxyuridine, 2-hydroxyisocaproic acid, 2-hydroxypyridine, 3-aminoisobutyric acid, 3-sulfinoalanine, 3-phenyllactic acid, 4-aminobutyric acid, 4-hydroxyphenyllactic acid, 4-hydroxyproline, 5-glutamylcysteine, N6-acetyllysine, N-acetylserine, S-adenosylhomocysteine, S-adenosylmethionine, aconitic acid, ascorbic acid, and acetylcholine. Acid, asparagine, aspartic acid, acetylcarnitine, azelaic acid, adenine, adenosine, adenosine monophosphate, adenosine 3',5'-cyclic monophosphate, arachidonic acid, alanine, allantoin, argininosuccinic acid, arginine, isoleucine, inosine, indoxyl sulfate, uridine, octadecanol, ornithine, oleic acid, caproic acid, galacturonic acid, carnitine, xanthine, xylose, kynurenine, quinolinic acid, guanosine, guanosine monophosphate, glyoxylic acid, glycolic acid, glycine, glycerin L-3-phosphate, glutamine, glutamic acid, creatinine, creatine, cholic acid, succinic acid, choline, cholesterol, cystathionine, cystine, cysteine, citicoline, cytidine, cytidine monophosphate, cytosine, citrulline, dihydrouracil, dihydroxyacetone phosphate, dimethylglycine, oxalic acid, scyllo-inositol, sucrose, stearic acid, serotonin, sorbose, symmetric dimethylarginine, dopa, dopamine, docosahexaenoic acid, tryptamine, tryptophan, trehalose, nicotine The molecule may be at least one molecule selected from the group consisting of amide, uric acid, paraxanthine, palmitic acid, pantothenic acid, histamine, histidine, asymmetric dimethylarginine, hydroquinone, hypoxanthine, hypoxanthine, hypotaurine, psicose, proline, boric acid, homocysteine, maleic acid, mannose, myristic acid, methionine sulfoxide, methionine sulfone, monostearin, lactitol, lactose, linoleic acid, ribulose, ribose, ribonic acid, malic acid, leucine, and uric acid.

[0030] (1B) When markers are detected by GC / MS of plasma samples, the markers are 1,6-anhydroglucose, 1-hexadecanol, 2-ketobutyric acid, 2'-deoxyuridine, 2-hydroxyisocaproic acid, 2-hydroxypyridine, 3-aminoisobutyric acid, 3-sulfinoalanine, 3-phenyllactic acid, 4-hydroxyphenyllactic acid, N6-acetyllysine, N-acetylserine, aconitic acid, ascorbic acid, azelaic acid, allantoin, indoxyl sulfate, uridine, octadecanol, oleic acid, caproic acid, galacturonic acid, xanthine, xylose, quinolinic acid, glyoxylic acid, glycolic acid, glycerol, and the like. The molecule may be at least one molecule selected from the group consisting of glycerol-3-phosphate, creatinine, cholesterol, cytosine, dihydrouracil, dihydroxyacetone phosphate, dimethylglycine, oxalic acid, scyllo-inositol, sucrose, stearic acid, sorbose, docosahexaenoic acid, tryptamine, trehalose, uric acid, paraxanthine, palmitic acid, pantothenic acid, histamine, hydroquinone, hypotaurine, psicose, boric acid, maleic acid, mannose, myristic acid, methionine sulfone, monostearin, lactitol, lactose, linoleic acid, ribulose, ribose, ribonic acid, malic acid, and uric acid.

[0031] (1C) When detecting markers by GC / MS of plasma samples, the markers that are affected by the time between blood collection and centrifugation are 1,6-anhydroglucose, 1-hexadecanol, 2-hydroxypyridine, 2-ketobutyric acid, 3-sulfinoalanine, aconitic acid, allantoin, arachidonic acid, ascorbic acid, azelaic acid, cytosine, dihydroxyacetone phosphate, glycerol-3-phosphate, histamine, hydroquinone, lactitol, maleic acid, mannose, methionine sulfone, N-acetylserine, and The molecule may be at least one molecule selected from the group consisting of octadecanol, oxalic acid, pantothenic acid, psicose, quinolinic acid, ribonic acid, ribulose, sorbose, sucrose, uridine, xanthine, xylose, docosahexaenoic acid, hypotaurine, trehalose, 2'-deoxyuridine, 3-aminoisobutyric acid, 4-hydroxyphenyllactic acid, cholesterol, dimethylglycine, indoxyl sulfate, lactose, linoleic acid, malic acid, monostearin, myristic acid, oleic acid, palmitic acid, stearic acid, and uric acid.

[0032] (1D) When detecting markers by GC / MS of a plasma sample, the marker that is affected by the time from when blood is drawn to when the blood is cooled can be at least one molecule selected from the group consisting of 1,6-anhydroglucose, 2'-deoxyuridine, 2-hydroxyisocaproic acid, 2-hydroxypyridine, 2-ketobutyric acid, 3-sulfinoalanine, 3-phenyllactic acid, allantoin, azelaic acid, dihydrouracil, dihydroxyacetone phosphate, docosahexaenoic acid, glycerol-3-phosphate, glycolic acid, glyoxylic acid, histamine, hydroquinone, hypotaurine, lactitol, lactose, maleic acid, mannose, methionine sulfone, N6-acetyllysine, N-acetylserine, oxalic acid, pantothenic acid, paraxanthine, psicose, quinolinic acid, ribose, ribulose, sucrose, trehalose, uric acid, uridine, and xanthine.

[0033] (1E) When detecting markers by GC / MS of plasma samples, the markers that are affected by the number of freeze-thaw cycles are 1,6-anhydroglucose, 2-hydroxypyridine, 3-sulfinoalanine, ascorbic acid, azelaic acid, boric acid, caproic acid, galacturonic acid, hydroquinone, lactose, methionine sulfone, pantothenic acid, psicose, quinolinic acid, ribonic acid, ribulose, sucrose, 2'-deoxyuridine, 2-hydroxyisocaproic acid, cytosine, and dihydroxyapatite. The molecule may be at least one selected from the group consisting of cetanol phosphate, glycerol-3-phosphate, indoxyl sulfate, mannose, monostearin, N6-acetyl lysine, N-acetyl serine, octadecanol, ribose, scyllo-inositol, trehalose, uridine, xanthine, xylose, 1-hexadecanol (cetanol), 3-phenyllactic acid, allantoin, creatinine, dimethylglycine, histamine, lactitol, maleic acid, and tryptamine.

[0034] (1F) When markers are detected by LC / MS of plasma samples, the markers are 2-aminobutyric acid, 4-aminobutyric acid, 4-hydroxyproline, 5-glutamylcysteine, S-adenosylhomocysteine, S-adenosylmethionine, asparagine, aspartic acid, acetylcarnitine, adenine, adenosine, adenosine monophosphate, adenosine 3',5'-cyclic monophosphate, alanine, allantoin, argininosuccinic acid, arginine, isoleucine, inosine, uridine, ornithine, carnitine, xanthine, kynurenine, guanosine, guanosine monophosphate, glycine, The molecule may be at least one molecule selected from the group consisting of choline, glutamine, glutamic acid, creatinine, creatine, cholic acid, succinic acid, choline, cystathionine, cystine, cysteine, citicoline, cytidine, cytidine monophosphate, citrulline, dimethylglycine, serotonin, symmetric dimethylarginine, symmetric dimethylarginine, dopa, dopamine, tryptophan, nicotinamide, pantothenic acid, histidine, asymmetric dimethylarginine, hypoxanthine, proline, homocysteine, methionine sulfoxide, malic acid, leucine, and uric acid.

[0035] (1G) When detecting markers by LC / MS of plasma samples, the markers that are affected by the time between blood collection and centrifugation are 5-glutamylcysteine, adenosine, adenosine monophosphate, allantoin, citicoline, cysteine, cytidine, cytidine monophosphate, dopa, guanosine monophosphate, hypoxanthine, inosine, nicotinamide, proline, S-adenosylhomocysteine, serotonin, succinic acid, 4-aminobutyric acid, adenine, arginine, aspartic acid, dopamine, guanosine, malic acid, pantothenic acid, The molecule may be at least one molecule selected from the group consisting of S-adenosylmethionine, succinic acid, xanthine, 2-aminobutyric acid, 4-hydroxyproline, acetylcarnitine, adenosine 3',5'-cyclic monophosphate, alanine, argininosuccinic acid, asymmetric dimethylarginine, carnitine, cholic acid, choline, citrulline, creatine, creatinine, cystathionine, cystine, dimethylglycine, isoleucine, kynurenine, leucine, methionine sulfoxide, symmetric dimethylarginine, tryptophan, uric acid, and uridine.

[0036] (1H) When detecting markers by LC / MS of a plasma sample, the marker that is affected by the time from when blood is drawn to when the blood is cooled can be at least one molecule selected from the group consisting of 4-aminobutyric acid, 5-glutamylcysteine, adenine, adenosine, adenosine monophosphate, allantoin, aspartic acid, asymmetric dimethylarginine, cholic acid, choline, citicoline, cysteine, cytidine, cytidine monophosphate, dimethylglycine, dopa, dopamine, guanosine monophosphate, hypoxanthine, inosine, nicotinamide, ornithine, proline, S-adenosylhomocysteine, S-adenosylmethionine, serotonin, and xanthine.

[0037] (1I) When detecting markers by LC / MS of plasma samples, the following markers are affected by the number of freeze-thaw cycles: 4-aminobutyric acid, 5-glutamylcysteine, adenine, adenosine, adenosine monophosphate, allantoin, arginine, argininosuccinic acid, choline, creatine, creatinine, cystathionine, cysteine, cytidine monophosphate, dopa, malic acid, S-adenosylhomocysteine, S-adenosylmethionine, succinic acid, xanthine, carnitine, and citicoline. , cytidine, guanosine, guanosine monophosphate, hypoxanthine, inosine, kynurenine, nicotinamide, serotonin, uridine, 4-hydroxyproline, alanine, asparagine, aspartic acid, cholic acid, citrulline, cystine, dimethylglycine, glutamic acid, glutamine, glycine, histidine, homocysteine, isoleucine, leucine, pantothenic acid, and symmetric dimethylarginine.

[0038] (For serum sample markers) (2A) For serum samples, the markers were 1,6-anhydroglucose, 1-hexadecanol, 2-aminooctanoic acid, 2-aminobutyric acid, 2-ketoisovaleric acid, 2-hydroxyglutaric acid, 2-hydroxypyridine, 3-aminoisobutyric acid, 3-aminopropionic acid (β-alanine), 3-indolepropionic acid, 3-sulfinoalanine, 3-hydroxyanthranilic acid, 3-hydroxyisovaleric acid, 3-hydroxypyruvic acid, 3-hydroxypropionic acid, 3-phenyllactic acid, 4-hydroxyphenyllactic acid, 4-hydroxyproline, 5-hydroxymethyl-2-furancarboxylic acid, N6-acetyllysine, N-acetylglutamine, N-acetylserine, S-adenosyltransferase, and N-acetylglutamine. aryl homocysteine, aconitic acid, adipic acid, ascorbic acid, asparagine, aspartic acid, acetylcarnitine, acetylglycine, acetoacetic acid, azelaic acid, adenine, adenosine, adenosine monophosphate, adenosine 3',5'-cyclic monophosphate, arachidonic acid, alanine, allantoin, argininosuccinic acid, arginine, allose, benzoic acid, isoleucine, inositol, inosine, uracil, uridine, eicosapentaenoic acid, erythrulose, octadecanol, ornithine, oleamide, cadaverine, caproic acid, galacturonic acid, carnitine, carnosine, xanthine, xylitol, xylulose, xylose, kynurenine, guanosine, guanosine 3',5'-Cyclic 1-phosphate, glyoxylic acid, glycolic acid, glycine, glycerol-3-phosphate, glucosamine, gluconic acid, glutamic acid, glutaric acid, creatinine, creatine, cholic acid, succinic acid, choline, sarcosine, cystine, cysteine, cytidine, citramalic acid, citrulline, dihydrouracil, dihydroxyacetone phosphate, dimethylglycine, oxalic acid, scyllo-inositol, sucrose, stearic acid, serine, serotonin, sorbitol, sorbose, tyramine, tyrosine, decanoic acid, dopa, dopamine, docosahexaenoic acid, tryptophan, threonine, threonic acid, trehalose, nicotinamide, paraxanthine, valine, pantothenic acid , histidine, asymmetric dimethylarginine, hydroxylamine, hypoxanthine, hypotaurine, pyridoxamine, pyruvic acid-oxime, pyruvic acid, phenylalanine, phenylpyruvic acid, phenylbutyric acid, psicose, putrescine, proline, pelargonic acid, boric acid, homocysteine, margaric acid, maleic acid, myo-inositol, myristic acid, mesoerythritol, methionine, methionine sulfoxide, monostearin, lactitol, lactose, ribitol, ribulose, ribose, ribonic acid, ribonic acid lactone, malic acid, leucine, benzoic acid, symmetric dimethylarginine, and uric acid.

[0039] (2B) When markers are detected by GC / MS of serum samples, the markers are 1,6-anhydroglucose, 1-hexadecanol, 2-aminooctanoic acid, 2-aminobutyric acid, 2-ketoisovaleric acid, 2-hydroxyglutaric acid, 2-hydroxypyridine, 3-aminoisobutyric acid, 3-aminopropionic acid, 3-indolepropionic acid, 3-sulfinoalanine, 3-hydroxyanthranilic acid, 3-hydroxyisovaleric acid, 3-hydroxypyruvic acid, 3-hydroxypropionic ... acid, 3-phenyllactic acid, 4-hydroxyphenyllactic acid, 4-hydroxyproline, 5-hydroxymethyl-2-furancarboxylic acid, N6-acetyllysine, N-acetylglutamine, N-acetylserine, aconitic acid, adipic acid, ascorbic acid, acetylglycine, acetoacetic acid, azelaic acid, adenosine, arachidonic acid, allantoin, arginine, allose, benzoic acid, inositol, uracil, eicosapentaenoic acid, erythrulose, octadecanol, oleamide, kaolin Daberin, caproic acid, galacturonic acid, xylitol, xylulose, xylose, glyoxylic acid, glycolic acid, glycerol-3-phosphate, glucosamine, gluconic acid, glutaric acid, sarcosine, citramalic acid, dihydrouracil, dihydroxyacetone phosphate, oxalic acid, scyllo-inositol, sucrose, stearic acid, sorbitol, sorbose, tyramine, decanoic acid, dopamine, docosahexaenoic acid, threonic acid, trehalose, paraxanthine, pantothenic acid, hydrochloric acid, glycerol-3-phosphate ... The at least one molecule selected from the group consisting of xylamine, hypoxanthine, hypotaurine, pyridoxamine, pyruvic acid-oxime, pyruvic acid, phenylpyruvic acid, phenylbutyric acid, psicose, putrescine, pelargonic acid, boric acid, margaric acid, maleic acid, myo-inositol, myristic acid, mesoerythritol, monostearin, lactitol, lactose, ribitol, ribulose, ribose, ribonic acid, ribonic acid lactone, benzoic acid, and uric acid.

[0040] (2C) When detecting markers by GC / MS of serum samples, the markers that are affected by the time between blood collection and centrifugation are 2-aminooctanoic acid, 2-hydroxypyridine, 3-hydroxyanthranilic acid, 3-hydroxypyruvic acid, 3-indolepropionic acid, 3-sulfinoalanine, acetylglycine, aconitic acid, adenosine, adipic acid, allantoin, ascorbic acid, azelaic acid, benzoic acid, cadaverine, citramalic acid, dihydrouracil, dihydroxyacetone phosphate, dopamine, erythrulose, glycerol-3-phosphate, glycolic acid, hypotaurine, hypoxanthine, lactitol, lactose, maleic acid, monostearin, N6-acetyllysine, octadecanol, oxalic acid, pantothenic acid, paraxanthine, and pyridinium. The molecule may be at least one molecule selected from the group consisting of oxamine, pyruvic acid, ribose, sorbose, sucrose, tyramine, uracil, xylose, 1,6-anhydroglucose, 2-hydroxyglutaric acid, 2-ketoisovaleric acid, 3-aminopropionic acid, acetoacetic acid, decanoic acid, galacturonic acid, galacturonic acid, glutaric acid, inositol, lactose, mesoerythritol, myo-inositol, myristic acid, psicose, putrescine, ribitol, ribonic acid lactone, ribulose, scyllo-inositol, sorbitol, threonic acid, trehalose, uric acid, xylitol, xylose, xylulose, 1-hexadecanol, 3-hydroxyisovaleric acid, 4-hydroxyproline, dihydrouracil, gluconic acid, N-acetylserine, phenylbutyric acid, and ribonic acid.

[0041] (2D) When detecting markers by GC / MS of serum samples, the markers that are affected by the time between the centrifugation of blood and the collection of serum obtained by centrifugation are 1,6-anhydroglucose, 1-hexadecanol, 2-aminooctanoic acid, 2-hydroxyglutaric acid, 2-hydroxypyridine, 3-sulfinoalanine, 4-hydroxyphenyllactic acid, 4-hydroxyproline, 5-hydroxymethyl-2-furancarboxylic acid, aconitic acid, adenosine, adipic acid, azelaic acid, benzoic acid, boric acid, cadaverine, citramalic acid, dihydrouracil, dopamine, erythrulose, galacturonic acid, hypoxanthine, lactitol, lactose, maleic acid, and The molecule may be at least one molecule selected from the group consisting of N-acetylserine, octadecanol, pantothenic acid, phenylbutyric acid, psicose, putrescine, pyruvic acid, ribitol, ribonic acid lactone, ribose, sucrose, trehalose, 2-aminobutyric acid, 3-hydroxypropionic acid, 3-hydroxypyruvic acid, 3-indolepropionic acid, acetoacetic acid, allantoin, dihydroxyacetone phosphate, glucosamine, hydroxylamine, lactose, monostearin, N6-acetyllysine, N-acetylglutamine, oxalic acid, paraxanthine, phenylpyruvic acid, pyruvic acid oxime, threonic acid, tyramine, uracil, and xylulose.

[0042] (2E) When detecting markers by GC / MS of serum samples, the markers that are affected by the number of freeze-thaw cycles are 1,6-anhydroglucose, 2-aminooctanoic acid, 2-hydroxypyridine, 3-hydroxypropionic acid, 3-phenyllactic acid, 3-sulfinoalanine, 4-hydroxyproline, acetoacetic acid, adenosine, boric acid, dihydrouracil, dihydrouracil, dihydroxyacetone phosphate, dopamine, erythrulose, erythrulose, glyoxylic acid, lactose, maleic acid, N6-acetyllysine, oleamide, oxalic acid, pantothenic acid, phenylbutyric acid, psicose, ribonic acid lactone, ribose, threonic acid, 3-hydroxyanthranilic acid, allose, cadaverine, lactose, octadecanol, psicose, uracil ... The glycerol may be at least one molecule selected from the group consisting of sill, 1-hexadecanol, 2-aminobutyric acid, 3-aminoisobutyric acid, 3-hydroxypyruvic acid, 3-indolepropionic acid, adipic acid, allantoin, arachidonic acid, arginine, azelaic acid, benzoic acid, caproic acid, citramalic acid, docosahexaenoic acid, eicosapentaenoic acid, glucosamine, glycolic acid, hydroxylamine, hypoxanthine, margaric acid, mesoerythritol, monostearin, N-acetylglutamine, pelargonic acid, paraxanthine, phenylpyruvic acid, putrescine, pyridoxamine, pyruvate-oxime, ribulose, sarcosine, sorbitol, sorbose, stearic acid, sucrose, trehalose, tyramine, and uric acid.

[0043] (2F) When markers are detected by LC / MS of serum samples, the markers are 2-aminobutyric acid, 4-hydroxyproline, S-adenosylhomocysteine, asparagine, aspartic acid, acetylcarnitine, adenine, adenosine, adenosine monophosphate, adenosine 3',5'-cyclic monophosphate, alanine, allantoin, argininosuccinic acid, arginine, isoleucine, inosine, uridine, ornithine, carnitine, carnosine, xanthine, kynurenine, guanosine, guanosine. The molecule may be at least one molecule selected from the group consisting of 3',5'-cyclic monophosphate, glycine, glutamic acid, creatinine, creatine, cholic acid, succinic acid, choline, cystine, cysteine, cytidine, citrulline, dimethylglycine, serine, serotonin, tyrosine, dopa, dopamine, tryptophan, threonine, nicotinamide, valine, pantothenic acid, histidine, asymmetric dimethylarginine, hypoxanthine, phenylalanine, proline, homocysteine, methionine, methionine sulfoxide, malic acid, leucine, symmetric dimethylarginine, and uric acid.

[0044] (2G) When detecting markers by LC / MS of a serum sample, the marker that is affected by the time from when blood is drawn to when the blood is subjected to centrifugation can be at least one molecule selected from the group consisting of adenosine, adenosine 3',5'-cyclic monophosphate, allantoin, aspartic acid, carnosine, choline, cytidine, dopa, glutamic acid, guanosine, guanosine 3',5'-cyclic monophosphate, hypoxanthine, inosine, malic acid, nicotinamide, ornithine, S-adenosylhomocysteine, uridine, xanthine, arginine, argininosuccinic acid, cysteine, methionine sulfoxide, serine, succinic acid, asparagine, proline, histidine, pantothenic acid, isoleucine, leucine, dopamine, and glycine.

[0045] (2H) When detecting markers by LC / MS of a serum sample, the marker that is affected by the time from centrifugation of blood to collection of the serum obtained by centrifugation can be at least one molecule selected from the group consisting of adenine, adenosine, adenosine monophosphate, argininosuccinic acid, carnosine, cystine, cytidine, glutamic acid, guanosine, guanosine 3',5'-cyclic monophosphate, inosine, malic acid, S-adenosylhomocysteine, serotonin, adenosine 3',5'-cyclic monophosphate, allantoin, aspartic acid, cysteine, hypoxanthine, methionine sulfoxide, proline, and xanthine.

[0046] (2I) When detecting markers by LC / MS of serum samples, the markers that are affected by the number of freeze-thaw cycles are adenine, adenosine, adenosine 3',5'-cyclic monophosphate, adenosine monophosphate, allantoin, carnosine, creatine, cysteine, cystine, cytidine, and guanosine. The molecule may be at least one molecule selected from the group consisting of 3',5'-cyclic monophosphate, hypoxanthine, inosine, kynurenine, methionine sulfoxide, succinic acid, uridine, xanthine, 2-aminobutyric acid, 4-hydroxyproline, alanine, arginine, argininosuccinic acid, asparagine, asymmetric dimethylarginine, carnitine, cholic acid, choline, citrulline, creatinine, dimethylglycine, dopa, glycine, guanosine, histidine, homocysteine, isoleucine, leucine, methionine, nicotinamide, S-adenosylhomocysteine, serine, symmetric dimethylarginine, threonine, tryptophan, tyrosine, uric acid, acetylcarnitine, aspartic acid, glutamic acid, malic acid, ornithine, pantothenic acid, phenylalanine, proline, serotonin, and valine.

[0047] The above-mentioned markers used for evaluating the quality of plasma samples and serum samples can be used as markers for detecting deteriorated plasma samples and markers for detecting deteriorated serum samples, respectively. Also provided is a method for detecting deteriorated samples, comprising determining that a plasma sample or a serum sample is deteriorated based on the detection of at least one molecule selected from these markers.

[0048] (Aspect) It will be appreciated by those skilled in the art that the exemplary embodiments described above are examples of the following aspects.

[0049] (Item 1) A method for evaluating a sample according to one embodiment includes obtaining a plasma sample prepared from human blood, detecting at least one molecule shown in (1A) above in the plasma sample, and evaluating the quality of the plasma sample based on the intensity of the molecule obtained by the detection. This allows the quality of the plasma sample to be accurately evaluated based on an appropriate marker.

[0050] (Item 2) In another embodiment of the sample evaluation method according to the sample evaluation method described in item 1, the detection is performed by gas chromatography / mass spectrometry to detect at least one molecule shown in (1B) above in the plasma sample. This allows accurate evaluation of the quality of the plasma sample based on a marker appropriate for detection by GC / MS.

[0051] (Item 3) In another embodiment of the sample evaluation method according to the sample evaluation method described in item 2, the detection includes detecting at least one molecule in the plasma sample as described in (1C) above, and evaluating the quality of the plasma sample based on the time from when the blood is collected to when the blood is subjected to centrifugation based on the intensity of the molecule obtained by the detection. This allows accurate evaluation of the quality of the plasma sample with respect to the time based on a marker appropriate for detection by GC / MS.

[0052] (Item 4) In another embodiment of the sample evaluation method according to the sample evaluation method described in item 2, the detection includes detecting at least one molecule in the plasma sample as described in (1D) above, and evaluating the quality of the plasma sample based on the time from when the blood is collected to when the blood is cooled based on the intensity of the molecule obtained by the detection. This allows accurate evaluation of the quality of the plasma sample with respect to the time based on a marker appropriate for detection by GC / MS.

[0053] (Item 5) In another embodiment of the method for evaluating a sample, the method for evaluating a sample according to item 2 includes detecting at least one molecule in the plasma sample as described in (1E) above, and evaluating the quality of the plasma sample based on the number of times the plasma sample has been subjected to freezing and thawing based on the intensity of the molecule obtained by the detection. This allows accurate evaluation of the quality of the plasma sample with respect to the number of times based on a marker appropriate for detection by GC / MS.

[0054] (Item 6) In another embodiment of the method for evaluating a sample, the method for evaluating a sample according to item 1 includes detecting at least one molecule shown in (1F) above in the plasma sample by liquid chromatography / mass spectrometry. This allows accurate evaluation of the quality of the plasma sample based on a marker appropriate for detection by LC / MS.

[0055] (Item 7) In another embodiment of the sample evaluation method according to the sample evaluation method described in item 6, the detection includes detecting at least one molecule in the plasma sample as described in (1G) above, and evaluating the quality of the plasma sample based on the time from when the blood is collected to when the blood is subjected to centrifugation based on the intensity of the molecule obtained by the detection. This allows accurate evaluation of the quality of the plasma sample with respect to the time based on a marker appropriate for detection by LC / MS.

[0056] (Item 8) In another embodiment of the sample evaluation method according to the sample evaluation method described in item 6, the detection includes detecting at least one molecule in the plasma sample as described in (1H) above, and evaluating the quality of the sample based on the time from when the blood is collected to when the blood is cooled based on the intensity of the molecule obtained by the detection. This allows accurate evaluation of the quality of the plasma sample with respect to the time based on a marker appropriate for detection by LC / MS.

[0057] (Item 9) In another embodiment of the method for evaluating a sample, the method for evaluating a sample according to item 6 includes detecting at least one molecule in the plasma sample as described in (1I) above, and evaluating the quality of the plasma sample based on the number of times the plasma sample has been subjected to freezing and thawing based on the intensity of the molecule obtained by the detection. This allows accurate evaluation of the quality of the plasma sample with respect to the number of times based on a marker appropriate for detection by LC / MS.

[0058] (Item 10) An analytical method according to another embodiment includes evaluating a plasma sample by the sample evaluation method according to any one of items 1 to 9, and analyzing the plasma sample based on the evaluation. This allows the conditions for sample preparation to be adjusted and the analysis to be performed with high accuracy.

[0059] (Item 11) A method for detecting a deteriorated sample according to another embodiment comprises obtaining a plasma sample prepared from human blood and detecting at least one molecule as described in (1A) above in the plasma sample, thereby enabling accurate evaluation of the quality of the plasma sample based on an appropriate marker.

[0060] (Item 12) A marker for detecting deteriorated plasma samples according to another embodiment includes at least one molecule as described in (1A) above. This allows accurate evaluation of the quality of a plasma sample.

[0061] (Item 13) A method for evaluating a sample according to one embodiment includes obtaining a serum sample prepared from human blood, detecting at least one molecule shown in (2A) above in the serum sample, and evaluating the quality of the serum sample based on the intensity of the molecule obtained by the detection. This allows the quality of the serum sample to be accurately evaluated based on an appropriate marker.

[0062] (Item 14) In another embodiment of the sample evaluation method according to the sample evaluation method described in item 13, the detection is performed by gas chromatography / mass spectrometry to detect at least one molecule shown in (2B) above in the serum sample. This allows accurate evaluation of the quality of the serum sample based on a marker appropriate for detection by GC / MS.

[0063] (Item 15) In another embodiment of the sample evaluation method, in the sample evaluation method described in item 14, the detection includes detecting at least one molecule shown in (2C) above in the serum sample, and evaluating the quality of the serum sample based on the time from when the blood is collected to when the blood is subjected to centrifugation based on the intensity of the molecule obtained by the detection. This allows the quality of the serum sample to be accurately evaluated for that time based on a marker appropriate for detection by GC / MS.

[0064] (Item 16) In another embodiment of the sample evaluation method according to the sample evaluation method described in item 14, the detection includes detecting at least one molecule shown in (2D) above in the serum sample, and evaluating the quality of the sample based on the time from centrifuging the blood to isolating the serum obtained by the centrifugation based on the intensity of the molecule obtained by the detection. This allows the quality of the serum sample to be accurately evaluated for that time based on a marker appropriate for detection by GC / MS.

[0065] (Item 17) In another embodiment of the method for evaluating a sample, the method for evaluating a sample according to item 14 includes detecting at least one molecule in the serum sample as described in (2E) above, and evaluating the quality of the serum sample based on the number of times the serum sample has been subjected to freezing and thawing based on the intensity of the molecule obtained by the detection. This allows accurate evaluation of the quality of the serum sample with respect to the number of times based on a marker appropriate for detection by GC / MS.

[0066] (Item 18) In another embodiment of the sample evaluation method according to the sample evaluation method described in item 13, the detection is performed by liquid chromatography / mass spectrometry to detect at least one molecule shown in (2F) above in the serum sample. This allows accurate evaluation of the quality of the serum sample based on a marker appropriate for detection by LC / MS.

[0067] (Item 19) In another embodiment of the sample evaluation method according to the sample evaluation method described in item 18, the detection includes detecting at least one molecule shown in (2G) above in the serum sample, and evaluating the quality of the serum sample based on the time from when the blood is collected to when the blood is subjected to centrifugation based on the intensity of the molecule obtained by the detection. This allows the quality of the serum sample that has changed over time to be accurately evaluated based on a marker appropriate for detection by LC / MS.

[0068] (Item 20) In another embodiment of the method for evaluating a sample, in the method for evaluating a sample according to item 18, the detection includes detecting at least one molecule in the serum sample as shown in (2H) above, and evaluating the quality of the serum sample based on the time from centrifuging the blood to isolating the serum obtained by the centrifugation based on the intensity of the molecule obtained by the detection. This allows the quality of the serum sample that has changed over time to be accurately evaluated based on a marker appropriate for detection by LC / MS.

[0069] (Item 21) In another embodiment of the method for evaluating a sample, in the method for evaluating a sample according to item 18, the detection includes detecting at least one molecule in the serum sample as described in (2I) above, and evaluating the quality of the serum sample based on the number of times the serum sample has been subjected to freezing and thawing based on the intensity of the molecule obtained by the detection. This allows accurate evaluation of the quality of the serum sample with respect to the number of times based on a marker appropriate for detection by LC / MS.

[0070] (Item 22) An analysis method according to another embodiment includes evaluating a serum sample by the sample evaluation method according to any one of items 13 to 21, and analyzing the serum sample based on the evaluation. This allows the sample preparation conditions to be adjusted and the analysis to be performed with high accuracy.

[0071] (Item 23) A method for detecting a deteriorated sample according to another embodiment comprises obtaining a serum sample prepared from human blood and detecting at least one molecule as described in (2A) above in the serum sample, thereby enabling accurate evaluation of the quality of the serum sample based on an appropriate marker.

[0072] (Item 24) A marker for detecting deteriorated serum samples according to another embodiment includes at least one molecule described in (2A) above. This allows accurate evaluation of the quality of serum samples.

[0073] The present invention is not limited to the above-described embodiment, and other aspects that are conceivable within the scope of the technical concept of the present invention are also included within the scope of the present invention. EXAMPLES

[0074] Examples of the above-described embodiment will be described below, but the present invention is not limited to the specific devices or conditions in the following examples.

[0075] We interviewed the facilities where blood samples were collected and where plasma and serum samples were stored, and obtained information on the acceptable ranges for the time from blood collection to centrifugation in the preparation of plasma and serum samples. Based on this information, plasma and serum samples were prepared under several different conditions.

[0076] Plasma sample preparation At room temperature, 5 mL of blood from a healthy individual was taken into a blood collection tube containing EDTA, the blood collection tube was inverted and mixed, and then cooled and left to stand at 4°C. Here, in order to investigate the effect on the detection intensity of molecules contained in the sample when the cooling time was 5 minutes or more compared to when it was within 1 minute, the blood sample was prepared under both the former and latter conditions. After standing, the blood sample was subjected to centrifugation at 4°C, 3000 rpm, and 15 minutes. Here, in order to investigate the effect on the detection intensity of molecules contained in the sample when the time from blood collection to centrifugation was 1 hour, 4 hours, 8 hours, and 12 hours compared to when it was 15 minutes, the blood sample was prepared under each of the conditions of 15 minutes, 1 hour, 4 hours, 8 hours, and 12 hours. After centrifugation, the blood sample was left at room temperature for 30 minutes, and plasma was separated during this 30 minutes. The obtained plasma sample was frozen and stored. Here, to investigate the effect on the detection intensity of molecules contained in a sample when the sample was frozen and then frozen and thawed four, six, and ten times compared to when the sample was frozen and thawed two times, the sample was frozen and thawed two, four, six, and ten times.

[0077] Serum sample preparation At room temperature, 4 mL of blood from a healthy individual was taken in a blood collection tube that did not contain an anticoagulant, and the blood collection tube was inverted to mix, and then left to stand at room temperature. After standing, the blood sample was centrifuged at room temperature, 3500 rpm, and 5 minutes. In order to investigate the effect on the detection intensity of molecules contained in the sample when the time from blood collection to centrifugation was 1 hour, 4 hours, 8 hours, and 12 hours compared to when the time from blood collection to centrifugation was 15 minutes, preparations were made under each of the conditions of 15 minutes, 1 hour, 4 hours, 8 hours, and 12 hours. After centrifugation, the sample was left at room temperature, and serum was separated during this time. In order to investigate the effect on the detection intensity of molecules contained in the sample when the time from blood collection to centrifugation was 1 hour and 6 hours compared to when the time was 30 minutes, preparations were made under each of the conditions of 30 minutes, 1 hour, and 6 hours. The obtained serum sample was frozen and stored. Here, to investigate the effect on the detection intensity of molecules contained in a sample when the sample was frozen and then frozen and thawed four, six, and ten times compared to when the sample was frozen and thawed two times, the sample was frozen and thawed two, four, six, and ten times.

[0078] analysis Frozen plasma and serum samples were subjected to GC / MS or LC / MS. In GC / MS, plasma and serum samples were methoximated and trimethylsilyl-2-methylphenylsulfonyl (TMS)-containing GC / MS.

[0079] GC / MS GC / MS was performed using a GCMS-TQ8040 (Shimadzu Corporation), a GC-MS equipped with an AOC-20i (Shimadzu Corporation) as an autosampler.

[0080] Gas Chromatography Conditions Number and order of washing before injection: 3 times (Washed twice with acetone, then once with pyridine) Number and order of washings after injection: 7 times (Washed five times with acetone, then twice with pyridine) Column: BPX5, inner diameter 0.25 mm, length 30 m, film thickness 0.25 μm (SGE) Column temperature: After maintaining at 60°C for 2 minutes, the temperature was increased at a rate of 15°C / min and maintained at 330°C for 3 minutes. Inlet temperature: 250℃ Carrier gas: Helium Carrier gas control mode: Linear velocity constant 39.0 cm / sec Sample introduction method: Split (split ratio 30:1) Injection volume: 1μL

[0081] Mass spectrometry conditions Ionization method: Electron ionization method Ionization voltage: 70V Ionization current: 60μA Interface temperature: 280℃ Ion source temperature: 200℃ Gain: Reference value (auto-tuning result relative value + 0.35 kV) Mode: Multiple Reaction Monitoring (MRM)

[0082] LC / MS LC / MS was performed using a triple quadrupole LC-MS, LCMS-8050 (Shimadzu Corporation).

[0083] Liquid chromatography conditions Analytical column: Discovery HS F5-3 (inner diameter 2.1 mm, length 150 mm, film thickness 3 μm) (Sigma-Aldrich) Column temperature: 40℃ Injection volume: 3μL Mobile phase: (A) 0.1% formic acid (dissolved in water) (B) 0.1% formic acid (dissolved in acetonitrile) Flow rate: 0.25mL / min Gradient program: Time (min) Concentration of mobile phase B (%) 0 0 2.0 0 5.0 25 11.0 35 15.0 95 20.0 95 20.1 0 25.0 Stop

[0084] Mass spectrometry conditions Ionization method: Electrospray temperature: Desolvation line (DL) temperature: 250℃ Heat block temperature: 400℃ Interface temperature: 300℃ Gas Flow: Nebulizer gas flow rate: 3.0L / min Drying gas flow rate: 10.0L / min Heating gas flow rate: 10.0L / min Mode: Multiple Reaction Monitoring (MRM)

[0085] result Compounds whose detection intensity increased or decreased by 30% or more when the time from blood collection to centrifugation in GC / MS analysis of plasma samples was 1 hour, 4 hours, 8 hours, and 12 hours compared to when the time was 15 minutes are shown in Table A. The increase / decrease rate in Table A is the relative detection intensity value, with the detection intensity when the time from blood collection to centrifugation was 15 minutes set as 1.

[0086] [Table 1]

[0087] Compounds whose detection intensity increased or decreased by 30% or more when the time from blood collection to cooling in GC / MS analysis of plasma samples was 5 minutes or more compared to when the time was 1 minute or less are shown in Table B. The increase or decrease rate in Table B is the relative detection intensity value, with the detection intensity when the time from blood collection to cooling was 1 minute or less.

[0088] [Table 2]

[0089] Compounds whose detection intensity increased or decreased by 30% or more when freeze-thawing was performed 4, 6, or 10 times compared to 2 times when analyzing plasma samples by GC / MS are shown in Table C. The increase or decrease rate in Table C is the relative detection intensity value, with the detection intensity when freeze-thawing was performed 2 times set as 1.

[0090] [Table 3]

[0091] Compounds whose detection intensity increased or decreased by 30% or more when the time from blood collection to centrifugation in LC / MS analysis of plasma samples was 1 hour, 4 hours, 8 hours, and 12 hours compared to when the time was 15 minutes are shown in Table D. The increase / decrease rate in Table D is the relative detection intensity value, with the detection intensity when the time from blood collection to centrifugation was 15 minutes set as 1.

[0092] [Table 4]

[0093] Compounds whose detection intensity increased or decreased by 30% or more when the time from blood collection to cooling in LC / MS analysis of plasma samples was 5 minutes or more compared to when the time was 1 minute or less are shown in Table E. The increase or decrease rate in Table E is the relative detection intensity value, with the detection intensity when the time from blood collection to cooling was 1 minute or less.

[0094] [Table 5]

[0095] Compounds whose detection intensity increased or decreased by 30% or more when freeze-thawing was performed 4, 6, or 10 times compared to when freeze-thawing was performed 2 times during LC / MS analysis of plasma samples are shown in Table F. The increase or decrease rate in Table F is the relative detection intensity value, with the detection intensity when freeze-thawing was performed 2 times set as 1.

[0096] [Table 6]

[0097] Compounds whose detection intensity increased or decreased by 30% or more when the time from blood collection to centrifugation in GC / MS analysis of serum samples was 1 hour, 4 hours, 8 hours, and 12 hours compared to when the time was 15 minutes are shown in Table G. The increase / decrease rate in Table G is the relative detection intensity value, with the detection intensity when the time from blood collection to centrifugation was 15 minutes set to 1.

[0098] [Table 7-1] [Table 7-2]

[0099] Compounds whose detection intensity increased or decreased by 30% or more when the time from centrifugation to fractionation in GC / MS analysis of serum samples was 1 hour or 6 hours compared to when it was 30 minutes are shown in Table H. The increase or decrease rate in Table H is the relative detection intensity value, with the detection intensity when the time from centrifugation to fractionation was 30 minutes set to 1.

[0100] [Table 8-1] [Table 8-2]

[0101] Compounds whose detection intensity increased or decreased by 30% or more when serum samples were frozen and thawed four, six, and ten times compared to two times when analyzed by GC / MS are shown in Table I. The increase or decrease rates in Table I are relative detection intensity values, with the detection intensity when frozen and thawed two times being taken as 1.

[0102] [Table 9-1] [Table 9-2]

[0103] Table J shows compounds whose detection intensity increased or decreased by 30% or more when the time from blood collection to centrifugation in LC / MS analysis of serum samples was 1 hour, 4 hours, 8 hours, and 12 hours compared to when the time was 15 minutes. The increase / decrease rate in Table J is the relative detection intensity value, with the detection intensity when the time from blood collection to centrifugation was 15 minutes set to 1.

[0104] [Table 10]

[0105] Compounds whose detection intensity increased or decreased by 30% or more when the time from centrifugation to fractionation in LC / MS analysis of serum samples was 1 hour or 6 hours compared to when it was 30 minutes are shown in Table K. The increase or decrease rate in Table K is the relative detection intensity value, with the detection intensity when the time from centrifugation to fractionation was 30 minutes set to 1.

[0106] [Table 11]

[0107] Compounds whose detection intensity increased or decreased by 30% or more when serum samples were frozen and thawed four, six, and ten times compared to two times when analyzed by LC / MS are shown in Table M. The increase or decrease rate in Table M is the relative detection intensity value, with the detection intensity when frozen and thawed two times being set as 1.

[0108] [Table 12]

[0109] The disclosures of the following priority applications are incorporated herein by reference: Japan Patent Application No. 2019-089363 (filed May 9, 2019)

Claims

1. Obtaining a plasma sample prepared from human blood; detecting 1-hexadecanol in the plasma sample; and evaluating that the quality of the plasma sample is low or deteriorated based on the intensity of 1-hexadecanol obtained by the detection.

2. 2. The method for evaluating a sample according to claim 1 , The method for evaluating a sample, wherein the detection comprises detecting 1-hexadecanol in the plasma sample by gas chromatography / mass spectrometry.

3. 3. The method for evaluating a sample according to claim 2, The detection includes detecting 1-hexadecanol in the plasma sample; A method for evaluating a sample, comprising evaluating the quality of the plasma sample based on the time from when the blood is collected to when the blood is subjected to centrifugation based on the intensity of 1-hexadecanol obtained by the detection.

4. 3. The method for evaluating a sample according to claim 2, The detection includes detecting 1-hexadecanol in the plasma sample; A method for evaluating a sample, comprising evaluating the quality of the plasma sample based on the number of times the plasma sample has been subjected to freezing and thawing, based on the intensity of 1-hexadecanol obtained by the detection.

5. Evaluating a plasma sample by the method for evaluating a sample according to any one of claims 1 to 4; and analyzing the plasma sample based on said evaluation.

6. Obtaining a plasma sample prepared from human blood; and detecting 1-hexadecanol in the plasma sample.

7. A marker for detecting degraded plasma samples, containing 1-hexadecanol.

8. Obtaining a serum sample prepared from human blood; detecting 1-hexadecanol in the serum sample; and evaluating that the quality of the serum sample is low or deteriorated based on the intensity of 1-hexadecanol obtained by the detection.

9. 9. The method for evaluating a sample according to claim 8, The method of evaluating a sample, comprising detecting 1-hexadecanol in the serum sample by gas chromatography / mass spectrometry.

10. 10. The method for evaluating a sample according to claim 9, The detection includes detecting 1-hexadecanol in the serum sample; A method for evaluating a sample, comprising evaluating the quality of the serum sample based on the time from when the blood is collected to when the blood is subjected to centrifugation based on the intensity of 1-hexadecanol obtained by the detection.

11. 10. The method for evaluating a sample according to claim 9, The detection includes detecting 1-hexadecanol in the serum sample; A method for evaluating a sample, in which the quality of the serum sample is evaluated based on the time from centrifugation of the blood to separation of the serum obtained by the centrifugation, based on the intensity of 1-hexadecanol obtained by the detection.

12. 10. The method for evaluating a sample according to claim 9, The detection includes detecting 1-hexadecanol in the serum sample; A method for evaluating a sample, comprising evaluating the quality of the serum sample based on the number of times the serum sample has been subjected to freezing and thawing, based on the intensity of 1-hexadecanol obtained by the detection.

13. Evaluating a serum sample by the method for evaluating a sample according to any one of claims 8 to 12; and analyzing the serum sample based on said evaluation.

14. Obtaining a serum sample prepared from human blood; A method for detecting a deteriorated sample, comprising detecting 1-hexadecanol in the serum sample.

15. A marker for detecting degraded serum samples containing 1-hexadecanol.

Citation Information

Patent Citations

  • Esterified fatty acid composition

    JP2006520803A